Nasus Pharma Ltd. (NSRX) vs Organon & Co. (OGN)

Nasus Pharma Ltd. and Organon & Co. are both Drug Manufacturers General companies. Organon & Co. is the larger, with a market value of $3.6B against $40.8M — 88.3× the size. Across the 9 metrics below, Organon & Co. leads on 6 and Nasus Pharma Ltd. on 3.

Valuation

Metric NSRX OGN Drug Manufacturers General median
P/E — 17.38 24.72
P/S — 0.59 3.35
P/B n/m 3.58 5.00
Price to free cash flow n/m 7.77 17.68
EV/EBITDA n/m 7.82 13.91
EV/Sales n/m 1.80 3.95
Earnings yield — 5.75% 2.92%
Free cash flow yield 0.00% 12.87% 4.42%

Profitability

Metric NSRX OGN Drug Manufacturers General median
Gross margin — 52.68% 72.77%
Operating margin — 13.45% 18.90%
Net margin — 3.41% 8.27%
Free cash flow margin 0.00% 7.57% 17.25%
Return on equity 0.00% 24.04% 6.97%
Return on assets 0.00% 1.57% 2.76%
Return on invested capital 0.00% 6.11% 6.30%

Growth

Metric NSRX OGN Drug Manufacturers General median
Revenue growth (TTM) — (2.45%) 6.79%
EPS growth (last fiscal year) (231.82%) (78.38%) —
Revenue growth, 5-year CAGR — (0.99%) 3.98%
Net income growth, 5-year CAGR — (38.70%) 0.42%

Health

Metric NSRX OGN Drug Manufacturers General median
Debt to equity 0.00 8.50 0.63
Current ratio 8.77 1.95 1.32
Net debt to EBITDA 0.26 5.62 1.15

Dividend

Metric NSRX OGN Drug Manufacturers General median
Dividend yield — 6.88% 3.57%
Payout ratio — 0.38 0.53

Size

Metric NSRX OGN Drug Manufacturers General median
Market cap 40.75m 3.60b 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack